Zacks Research Has Pessimistic Outlook of BIO Q2 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research reduced their Q2 2026 earnings estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Friday, May 22nd. Zacks Research analyst Team now expects that the medical research company will post earnings of $2.34 per share for the quarter, down from their prior estimate of $2.38. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.42 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2027 earnings at $2.39 EPS.

BIO has been the topic of several other research reports. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a report on Friday, May 15th. They issued an “outperform” rating and a $320.00 price objective on the stock. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Wells Fargo & Company cut their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research note on Friday, May 1st. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of “Hold” and a consensus price target of $303.33.

Bio-Rad Laboratories Stock Up 3.1%

Shares of NYSE BIO opened at $296.52 on Wednesday. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $343.12. The business’s 50 day moving average is $275.82 and its two-hundred day moving average is $291.91. The firm has a market cap of $7.93 billion, a price-to-earnings ratio of 48.85 and a beta of 1.06. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company had revenue of $592.10 million during the quarter, compared to analyst estimates of $589.91 million. During the same quarter in the prior year, the company posted $2.54 earnings per share. The business’s revenue was up 1.1% compared to the same quarter last year.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Natixis Advisors LLC grew its position in shares of Bio-Rad Laboratories by 67.1% in the 3rd quarter. Natixis Advisors LLC now owns 65,069 shares of the medical research company’s stock valued at $18,245,000 after buying an additional 26,119 shares during the last quarter. Mangrove Partners IM LLC acquired a new position in Bio-Rad Laboratories in the third quarter valued at $35,568,000. Gotham Asset Management LLC grew its holdings in shares of Bio-Rad Laboratories by 41.8% during the third quarter. Gotham Asset Management LLC now owns 124,626 shares of the medical research company’s stock worth $34,944,000 after purchasing an additional 36,763 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Bio-Rad Laboratories by 461.0% in the 3rd quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock valued at $2,520,000 after purchasing an additional 7,386 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Bio-Rad Laboratories by 36.0% in the 3rd quarter. Assetmark Inc. now owns 28,808 shares of the medical research company’s stock valued at $8,077,000 after purchasing an additional 7,633 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.